Artificial Intelligence
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Continued progress in dose-escalation study with zotatifin in combination with fulvestrant in ER+ mBC,
with data anticipated in the second half of 2023
Raised $16.2 million in gross proceeds from two registered direct financings, extending cash runway into second quarter of 2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
“It was another productive quarter for eFFECTOR as we made considerable progress on all fronts,” remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. “The data presented at ASCO was a significant milestone for the zotatifin program, with substantially greater activity observed with the ZFA triplet than we would have expected in such heavily pretreated patients with just fulvestrant and abemaciclib. While still immature, we are encouraged by the emerging PFS data for the ZFA triplet and look forward to disclosing mature PFS data along with further dose escalation data later this year. We are now focusing on defining our registrational path for zotatifin in ER+ mBC and believe that the drug can be positioned as a second line therapy in multiple patient segments, with and without defined resistance mutations.”
“The randomized Phase 2b KICKSTART clinical trial of tomivosertib combined with pembrolizumab for the treatment of non-small cell lung cancer (NSCLC) continues to progress, with an anticipated data readout in the second half of 2023,” continued Dr. Worland. “In addition, we are thrilled to welcome Dr. Gary Chiang back to eFFECTOR as the Vice President of Translational Science, as we continue to build up internal expertise to support both tomivosertib and zotatifin development programs. Lastly, we bolstered our balance sheet by raising over $16.0 million during the quarter, which now extends our cash runway into the second quarter of 2024.”
Pipeline Highlights
Tomivosertib (eFT508): eFFECTOR’s wholly owned, highly selective MNK inhibitor designed to enhance anti-tumor immune activity by activating T cells, delaying their exhaustion, and expanding the pool of central memory T cells:
- Enrollment continues in Phase 2b KICKSTART trial in NSCLC. eFFECTOR’s KICKSTART trial is continuing to enroll patients with PD-L1 expression ≥50% who will receive tomivosertib or placebo in combination with pembrolizumab as their initial therapy for metastatic disease. Topline data are anticipated in the second half of 2023.
Zotatifin (eFT226): eFFECTOR’s wholly-owned, potent and selective inhibitor of mRNA helicase eIF4A designed to downregulate expression of key oncoproteins and cell cycle proteins that drive tumor growth and resistance:
- Positive clinical data for ZFA triplet in ER+ breast cancer was presented at ASCO Annual Meeting 2023 in June, with partial responses seen in 26% of patients. New interim data were presented on the fully enrolled expansion cohort of patients (n=20) who received the ZFA triplet with zotatifin dosed at 0.07 mg/kg on Days 1 and 8 of 21-day cycles. Patients were heavily pre-treated, having received a median of four prior lines of therapy for metastatic disease. Five out of 19 (26%) RECIST-evaluable patients achieved a partial response (PR), including four confirmed and one unconfirmed. All five patients who achieved a PR had previously progressed on prior CDK4/6 and fulvestrant treatments, and all five had received one or more prior lines of chemotherapy. Efficacy results exceeded our expectations for fulvestrant and abemaciclib (FA doublet) in such heavily pre-treated patients after CDK4/6, endocrine and/or chemotherapies. The ZFA triplet was generally well tolerated, with three patients discontinuing due to adverse events (AEs) of any cause, and the large majority of AEs being Grade 1 or 2. Mature PFS data from the ZFA cohort is anticipated in the second half of 2023.
- On track to report topline data from dose escalation in the second half of 2023. Favorable safety results generated to date have allowed resumption of dose escalation to determine the recommended Phase 2 dose of zotatifin combined with fulvestrant (ZF doublet). Topline data from dose escalation are anticipated in the second half of 2023.
- Collaboration with Stanford Medicine on investigator-initiated randomized Phase 2 study in patients with ER+ breast cancer. This trial, being led by Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine, is bringing to the clinic the science of integrative subgroups of breast cancer, building on work done by Christian Curtis, Ph.D., Professor of Medicine, Genetics, and Biomedical Data Science, and Director of Artificial Intelligence and Cancer Genomics at Stanford Medicine. Zotatifin will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive of relapse.
Business Highlights
- $16.2 million in gross proceeds raised from two registered direct financings, extending cash runway into second quarter of 2024. eFFECTOR completed two registered direct financings during the second quarter of 2023. The first financing closed on May 31, 2023, and included the sale of an aggregate of 11,450,382 shares of common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.655 per share (or common stock equivalent in lieu thereof), and unregistered warrants to purchase up to an aggregate of 11,450,382 shares of common stock with an exercise price of $0.53 per share. The second financing closed on June 8, 2023, and included the sale of an aggregate of 7,764,445 shares of common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.125 per share (or common stock equivalent in lieu thereof), and unregistered warrants to purchase up to an aggregate of 7,764,445 shares of common stock with an exercise price of $1.00 per share. With the completion of the two financings, eFFECTOR has extended the previously anticipated cash runway from first quarter of 2024 into the second quarter of 2024.
- eFFECTOR hired Gary Chiang, Ph.D., as Vice President of Translational Science. eFFECTOR welcomes back Gary Chiang, Ph.D., as Vice President of Translational Science. Dr. Chiang brings over 20 years of experience in drug discovery and cancer research. He most recently served as Executive Director, Head of Biology at Erasca, Inc., and previously held the position of Executive Director, Cancer Biology at eFFECTOR, where he led pre-clinical and translational efforts on the tomivosertib and eIF4E programs. Prior to eFFECTOR, Dr. Chiang was Senior Group Leader, Oncology Discovery at AbbVie. Earlier in his career, Dr. Chiang was a research assistant professor at the Sanford-Burnham Medical Research Institute following a NIH-NRSA postdoctoral fellowship. He completed his Ph.D. in Biology at the University of California, San Diego / Salk Institute for Biological Studies and he received his B.S. with distinction in Biochemistry from the University of Illinois at Urbana-Champaign.
Second Quarter 2023 Financial Results
Cash Position and Guidance: eFFECTOR had cash, cash equivalents, and short-term investments totaling $25.0 million as of June 30, 2023, compared to $19.0 million as of March 31, 2023. eFFECTOR completed two registered direct financings during the second quarter of 2023, with aggregate gross proceeds totaling $16.2 million. eFFECTOR anticipates that its current cash, cash equivalents and short-term investments will be sufficient to fund operations into the second quarter of 2024.
Research and Development (R&D) Expenses: R&D expenses were $4.9 million for the quarter ended June 30, 2023, compared to $6.9 million for the same quarter of 2022. This decrease for the quarter was due to lower external development expenses primarily associated with the timing of clinical trial activities and manufacturing related activities for both the tomivosertib and zotatifin programs. R&D expenses included approximately $0.5 million and $0.7 million of non-cash stock compensation expense in the quarters ended June 30, 2023 and 2022, respectively.
General and Administrative (G&A) Expenses: G&A expenses were $3.0 million for each of the quarters ended June 30, 2023 and 2022. Employee related costs increased by approximately $0.2 million for the three months ended June 30, 2023 compared to the same period in 2022, due to higher non-cash stock compensation and bonus expense, along with a $0.2 million increase in legal and patent costs, offset by a reduction of $0.4 million in relation to D&O insurance for the three months ended June 30, 2023 compared to the same period in 2022. G&A expenses included approximately $0.7 million and $0.6 million of non-cash stock compensation expense in the quarters ended June 30, 2023 and 2022, respectively.
Other Income (Expense): Other expense was $0.5 million for the quarter ended June 30, 2023 and other income for the quarter ended June 30, 2022 was $1.0 million. Other expense in the quarter ended June 30, 2023 consisted primarily of interest expense associated with the company’s term loans, which was partially offset by interest income. Other income in the quarter ended June 30, 2022 consisted primarily of income related to the change in fair value of the company’s earn-out liability for the period, partially offset by interest expense associated with the company’s term loans. The fair value of the share earn-out liability of $1.4 million at March 31, 2022 was remeasured at $0.1 million as of June 30, 2022 and $6 thousand as of June 30, 2023.
Net Loss: Net loss was $8.4 million, or $0.17 per basic and diluted share, for the quarter ended June 30, 2023, as compared to $6.9 million, or $0.17 per basic and diluted share, for the same quarter of 2022.
About eFFECTOR Therapeutics
eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.
Forward-Looking Statements
eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the future clinical development of our product candidates, including expectations on enrollment and the timing of reporting data from ongoing clinical trials; the planned expanded development of zotatifin and the timing thereof; the potential therapeutic benefits of our product candidates; and the sufficiency of our capital resources to fund operations into the second quarter of 2024 and allow clinical data readouts and the expansion of our clinical development programs. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of our clinical trials and preclinical studies for our product candidates is uncertain; we may use our capital resources sooner than expected and they may be insufficient to allow clinical trial readouts; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; our ability to obtain and maintain intellectual property protection for our product candidates; any future impacts to our business resulting from inflation or the conflict between Russia and Ukraine or other geopolitical developments outside our control; and other risks described in our prior filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
| eFFECTOR Therapeutics, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (in thousands) | |||||||
| June 30, 2023 | December 31, 2022 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 14,714 | $ | 8,708 | |||
| Short-term investments | 10,305 | 17,602 | |||||
| Prepaid expenses and other current assets | 956 | 1,704 | |||||
| Total current assets | 25,975 | 28,014 | |||||
| Property and equipment, net | 216 | 241 | |||||
| Operating lease right-of-use assets | 83 | 111 | |||||
| Other assets | 615 | 711 | |||||
| Total assets | $ | 26,889 | $ | 29,077 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,451 | $ | 1,486 | |||
| Accrued expenses | 1,923 | 3,368 | |||||
| Current term loans, net | 19,216 | 19,061 | |||||
| Accrued final payment on term loans, current | 1,100 | 1,100 | |||||
| Lease liabilities, current portion | 69 | 60 | |||||
| Total current liabilities | 23,759 | 25,075 | |||||
| Other accrued liabilities, non-current | 484 | — | |||||
| Earn-out liability | 6 | 6 | |||||
| Non-current warrant liability | 40 | 40 | |||||
| Non-current lease liabilities | 25 | 60 | |||||
| Total liabilities | 24,314 | 25,181 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock | — | — | |||||
| Common stock | 6 | 4 | |||||
| Additional paid-in capital | 164,512 | 147,476 | |||||
| Accumulated other comprehensive income (loss) | 1 | (18 | ) | ||||
| Accumulated deficit | (161,944 | ) | (143,566 | ) | |||
| Total stockholders’ equity | 2,575 | 3,896 | |||||
| Total liabilities and stockholders’ equity | $ | 26,889 | $ | 29,077 | |||
| eFFECTOR Therapeutics, Inc. | |||||||||||||||
| Condensed Consolidated Statement of Operations and Comprehensive loss | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Grant revenue | $ | – | $ | 2,011 | $ | – | $ | 2,011 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 4,881 | 6,919 | 11,490 | 10,031 | |||||||||||
| General and administrative | 2,974 | 2,973 | 5,901 | 6,409 | |||||||||||
| Total operating expenses | 7,855 | 9,892 | 17,391 | 16,440 | |||||||||||
| Operating loss | (7,855 | ) | (7,881 | ) | (17,391 | ) | (14,429 | ) | |||||||
| Other income (expense) | |||||||||||||||
| Interest income | 227 | 64 | 453 | 88 | |||||||||||
| Interest expense | (722 | ) | (505 | ) | (1,411 | ) | (983 | ) | |||||||
| Other income (expense), net | (14 | ) | 123 | (29 | ) | (563 | ) | ||||||||
| Change in fair value of earn-out liability | — | 1,284 | — | 12,041 | |||||||||||
| Other income (expense) | (509 | ) | 966 | (987 | ) | 10,583 | |||||||||
| Net loss | (8,364 | ) | (6,915 | ) | (18,378 | ) | (3,846 | ) | |||||||
| Other comprehensive income (loss) | — | (32 | ) | 19 | (82 | ) | |||||||||
| Comprehensive loss | $ | (8,364 | ) | $ | (6,947 | ) | $ | (18,359 | ) | $ | (3,928 | ) | |||
| Net loss per share, basic and diluted | $ | (0.17 | ) | $ | (0.17 | ) | $ | (0.41 | ) | $ | (0.09 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 47,828,631 | 41,118,727 | 44,930,987 | 40,984,273 | |||||||||||
Contacts:
| Investors: | Media: | |
| Christopher M. Calabrese Managing Director LifeSci Advisors 917-680-5608 [email protected] |
Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 [email protected] |
Mike Tattory Account Supervisor LifeSci Communications 609-802-6265 [email protected] |
Artificial Intelligence
Aon and Marsh McLennan call on (re)insurance industry to aid Ukraine’s resilience
– The firms emphasized that the removal of blanket exclusions would catalyze Ukraine’s growth and future reconstruction
MONTE CARLO, Sept. 8, 2024 /PRNewswire/ — Aon and Marsh McLennan today called on the (re)insurance industry to build upon the capital, expertise and historical role of the (re)insurance industry to help Ukraine’s resilience by catalyzing economic growth and strengthening the country’s foundations for a post-conflict economy. The firms emphasized that the removal of blanket exclusions, which ignore the diversity of risk throughout the country, would further support for Ukraine’s economy.
Additionally, since the start of the war, many global reinsurers have grouped risks originating in Ukraine, Russia, and Belarus together, excluding them from reinsurance contracts, limiting (re)insurance capital and impeding economic growth and stability. The inclusion of Ukraine with Russia and Belarus is not rooted in the data and analytics that drive the assessment of risk and overlooks that Ukraine, while under siege, seeks to further align as a free and democratic economy and member of the European Union.
“Marsh McLennan is dedicated in our support of Ukraine – helping it attract global investment to rebuild the country, and recover from the devastating impact of war on its people and economy,” said John Doyle, president and CEO of Marsh McLennan. “We call on the global insurance community to join us in this effort and end blanket exclusions for Ukraine.”
“Aon’s support of Ukraine leads us to look forward to its economic recovery,” said Greg Case, CEO of Aon. “Insurance capital is essential for the reconstruction of Ukraine’s health care, energy and agricultural sectors. We’re asking the insurance industry to look closely at Ukraine’s risks and work to strengthen the public private partnerships under development.”
Marsh McLennan and Aon each are already working with the Ukraine, U.S. and UK governments, along with many other international organizations, to support Ukraine’s economy as it endures ongoing attacks and accelerate investment in the country’s eventual economic recovery.
In March, Marsh McLennan announced the expansion of its public-private partnership with the Ukraine government to cover all shipping to and from Ukraine’s ports. This follows Marsh McLennan’s support in helping the Ukraine Government develop its war risk data platform which provides investors and (re)insurers with granular transparent data on the impact of the conflict to date and degree of war risk.
In June, Aon worked with the U.S. International Development Finance Corporation to create a first-of-its-kind insurance program to support war risk policies for businesses operating in Ukraine. The availability of insurance for war risk, especially across health care and agriculture, will stimulate economic expansion and employment, while strengthening the foundation of Ukraine’s economy to support a robust reconstruction.
The firms assert that arbitrary exclusions for Ukraine contribute to confusion about the vastly different levels of risk in the country. As a result, there are potential issues with how (re)insurers underwrite risks between regions directly impacted by the war and many areas of central and western Ukraine which have suffered little to no war damage. The use of data and analytics can enable more impactful insights into where insurance capital can contribute to Ukraine’s reconstruction and further economic growth.
About AonAon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.
Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.
About Marsh McLennanMarsh McLennan (NYSE: MMC) is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. With annual revenue of $23 billion and more than 85,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit marshmclennan.com, or follow on LinkedIn and X.
Media Contacts
[email protected] (U.S., Canada and Puerto Rico): +1 833 751 8114International: +1 312 381 3024
Marsh McLennanJason [email protected]+44 (0)7733 325 587
Logo – https://mma.prnewswire.com/media/1632623/Aon_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/aon-and-marsh-mclennan-call-on-reinsurance-industry-to-aid-ukraines-resilience-302241050.html
Artificial Intelligence
HONOR Redefines Mobile AI Solutions with PC powered by Snapdragon, on-device AI Agent and AI Deepfake Detection at IFA 2024
HONOR, Qualcomm, and Microsoft Redefine Innovations in Mobile AI
BERLIN, Sept. 7, 2024 /PRNewswire/ — Today at IFA 2024, HONOR unveiled three groundbreaking mobile AI Solutions: AI PC powered by Snapdragon® X Elite platforms, AI Agent and AI Deepfake Detection. The launch was accompanied by a thought-provoking panel discussion featuring HONOR CEO George Zhao; Alex Katouzian, Group GM of MCX at Qualcomm Technologies, Inc.; and Mark Linton, VP of Device Partner Sales at Microsoft. Together, they explored the convergence of AI and Snapdragon technology, discussing how these innovations are shaping the future of mobile AI.
“When it comes to mobile computing, AI is not just a buzzword, it’s a revolution,” commented George Zhao, CEO of HONOR Device Co., Ltd. “At HONOR, we’re committed to working with our partners to deliver powerful AI capabilities and seamless connectivity, while protecting our users’ privacy. Through open collaboration with industry leaders, we’re creating devices that empower individuals and redefine what’s possible.”
“At Qualcomm Technologies, we believe the NPU is the key to unlocking the true potential of AI in PCs,” added Alex Katouzian, Group GM of MCX, Qualcomm Technologies, Inc. “The Snapdragon X Elite with its industry-leading NPU performance empowers AI PCs like the HONOR MagicBook Art 14 to deliver next-generation AI experiences. Not only will users see a significant boost in capabilities, but the NPU’s efficiency also translates to longer battery life, allowing users to stay productive for extended periods.”
HONOR MagicBook Art 14 Snapdragon: Redefining PC in the Mobile AI EraThe PC landscape is undergoing a radical transformation, driven by advancements in AI and the rise of Snapdragon platforms. Fueled by HONOR’s platform-level AI capabilities and developed in collaboration with top industry leaders, HONOR MagicBook Art 14 Snapdragon heralds a new era of computing.
Featuring a sleek and compact design, the HONOR MagicBook Art 14 Snapdragon is a marvel of lightweight engineering. It incorporates cutting-edge platform-level AI features alongside robust hardware and software solutions, ensuring unmatched productivity and user experience. It translates the lightweight and slim characteristics of smartphones to laptops, delivering the lightest and slimmest AI PC on the market, weighing approximately 1kg with a slimness of 1cm. Delivering an immersive visual journey, the HONOR MagicBook Art 14 Snapdragon features a captivating 14.6-inch HONOR FullView Touch Display boasting a crystal-clear 3.1K resolution. It also includes an outstanding 97% screen-to-body ratio, the largest among 14-inch laptops. The HONOR MagicBook Art 14 Snapdragon is powered by the Qualcomm Snapdragon X Elite, elevating the computing experience to new heights in terms of power, efficiency, and security.
The HONOR MagicBook Art 14 Snapdragon also enables a smooth transition of Windows applications on X86 to the Windows on Snapdragon architecture. Based on years of research on the ecosystem, HONOR created a Hotspot Library that uses platform-level AI to identify frequently used scenarios and trigger translation optimization efficiently. HONOR has improved 16% of the average boot-up time1 with translation optimization across a diverse array of Windows applications. Currently, HONOR has optimized a total of the Top 14 applications across six major categories, including browsers, online meetings, media, office, social software and tools.
The HONOR MagicBook Art 14 Snapdragon will be soon available in German, France and Italy. For preorder, please visit HONOR online store now at www.honor.com.
Seamless AI Experiences Elevated by the Power of MagicRingIn the mobile AI era, seamless cross-OS connectivity will truly empower users to unlock AI everywhere. Unlike the manual point-to-point connections in traditional solutions, the HONOR MagicRing allows multiple devices of the same account to automatically connect with low power consumption.
The MagicRing not only connects devices but also connects services across the devices. The solution also enables users to use the same set of keyboard and mouse for multiple devices, receive calls and notifications on a device other than their smartphones, and control the smartphone’s camera on the PC. With the secure and smooth flow of services and information across devices, MagicRing makes multi-device AI experience easier. For example, as one of the typical scenarios of Windows on Snapdragon experience, Cocreator allows users to produce fantastic artwork with simple draws. Powered by MagicRing, users can seamlessly access Cocreator on their HONOR MagicPad 2, drawing AI masterpieces with their Magic-Pencil. In the Meanwhile, they can also use AI Eraser from HONOR Magic V3 on the HONOR MagicBook Art 14 Snapdragon to experience unparalleled levels of convenient mobile AI.
HONOR AI Agent: The First On-device AI Agent for the Open Ecosystem The HONOR AI Agent is a revolutionary always-on personal assistant designed to enhance and simplify users’ daily lives. By intuitively understanding users’ requests and intentions through language analysis and UI awareness technology, the AI Agent that learns from their habits and device environment can intelligently make decisions across various apps and services. This capability allows it to automate complex tasks. HONOR demonstrated how to find and cancel unwanted app subscriptions across different apps with just a few simple voice commands on their smartphones.
As we look to the future, the HONOR AI Agent is poised to become the cornerstone of mobile AI, and it is anticipated to arrive with the HONOR Magic7 Series later this year in China. This innovation not only signifies a leap in technology but also heralds a new era where AI seamlessly integrates into our daily routines, enhancing everyday productivity and efficiency.
The World’s First On-device AI Deepfake Detection TechnologyAs the technology behind deepfakes becomes more sophisticated, the potential for misuse, including identity theft and the spread of disinformation, grows significantly. HONOR’s on-device AI Deepfake Detection represents a groundbreaking solution designed to protect users from the increasingly prevalent threat of deepfakes. This innovative detection system employs advanced algorithms to meticulously analyze various elements, including pixel-level synthetic imperfections, border compositing artifacts, inter-frame continuity, consistency in face-to-ear hairstyle, and the positioning of synthetic traces. By examining these characteristics, the technology can accurately identify manipulated content, distinguishing between genuine media and deceptive alterations.
About HONOR HONOR is a leading global provider of smart devices. It is dedicated to becoming a global iconic technology brand and creating a new intelligent world for everyone through its powerful products and services. With an unwavering focus on R&D, it is committed to developing technology that empowers people around the globe to go beyond, giving them the freedom to achieve and do more. Offering a range of high-quality smartphones, tablets, laptops and wearables to suit every budget, HONOR’s portfolio of innovative, premium and reliable products enable people to become a better version of themselves.
For more information, please visit HONOR online at www.honor.com or email [email protected]
https://community.honor.com/ https://www.facebook.com/honorglobal/ https://twitter.com/Honorglobal https://www.instagram.com/honorglobal/ https://www.youtube.com/c/HonorOfficial
1Data comes from HONOR labs.
View original content:https://www.prnewswire.co.uk/news-releases/honor-redefines-mobile-ai-solutions-with-pc-powered-by-snapdragon-on-device-ai-agent-and-ai-deepfake-detection-at-ifa-2024-302241211.html
Artificial Intelligence
TECNO Pocket Go Wins Global Product Technology Innovation Award 2024 at IFA 2024
BERLIN, Sept. 7, 2024 /PRNewswire/ — One of the largest consumer electronics exhibitions in the world, the 2024 IFA Berlin International Consumer Electronics Show, officially kicks off today in Berlin. During the event, the highly anticipated Global Product Technical Innovation Award 2024 was announced, with TECNO Pocket Go winning the prestigious AR Immersive PC Gaming Experience Innovation Gold Award. This recognition highlights the brilliance of Chinese brand on the global stage.
TECNO is dedicated to innovation from the user’s perspective, continuously developing products and applications that enhance user experience. Since 2019, TECNO has expanded its AIoT ecosystem, leveraging its mobile technology to introduce innovative smart wearables, business laptops, and other groundbreaking products, all aimed at providing users with a more intelligent TECNO ecosystem experience.
As a global innovative technology brand with operations in over 70 markets, TECNO has been committed to revolutionizing the digital experience in global emerging markets, relentlessly pushing for the perfect integration of contemporary, aesthetic design with the latest technologies. TECNO offers a wide range of AIoT products covering smart wearables, laptops, tablets and smart home products.
Guided by its brand essence of “Stop At Nothing”, TECNO is committed to unlocking the best and newest technologies for forward-looking individuals, inspiring them to never stop pursuing their best selves and their best futures.
The “Global Product Technology Innovation Award” is a grand international selection of global consumer electronics brands. Launched globally every year, it is also one of the most professional and authoritative international exchange, display and cooperation platforms in IFA in the same year to conduct comprehensive review and evaluation of the global consumer electronics industry for the whole year.
TECNO Pocket Go, redefines gaming on the go
TECNO Pocket Go creates a “new gaming paradise” in handheld PC form in AR industry. By seamlessly integrating with the Windows gaming ecosystem and utilizing advanced head tracking technology, it brings an unparalleled 6D immersive experience to users. Featuring a top-tier AMD® Ryzen™ 7 8840HS gaming processor and a laptop level cooling system by rebuilt the structure to compact size with 50% smaller size and 30% lighter weight. Just easy to carry as a smartphone.
Smaller in your palm, Master in your vision
The AR Pocket Vision features a 0.71-inch Micro-OLED screen that delivers the equivalent of a 215-inch TV experience from 6 meters away, surpassing industry standards. Gamers will enjoy a cinematic-level viewing experience, with customizable adjustments for up to 600° diopters to ensure eye comfort. It also safeguards your privacy, enabling you to play anywhere.
Dominant Flagship Gaming CPU, lead Performance Ahead
Powered by the AMD® Ryzen™ 7 8840HS gaming processor, the Pocket Go handheld offers exceptional speed and seamless multitasking with 8 cores, 16 threads, and turbo speeds up to 5.1 GHz. Its PC-level cooling system, featuring a large fan and three copper pipes, ensures optimal performance at 35W. Combined with a 50Wh replaceable battery, it guarantees long-lasting gaming sessions without interruptions.
“VisionTrack” experiences, games come alive
The Pocket Go combo delivers an immersive experience for your eyes and hands. The AR Pocket Vision features a six-axis gyroscope and AI algorithms for precise head tracking, enhancing real-time data collection during gameplay. With N’BASS® acoustic materials and a proprietary vibration algorithm, it translates in-game sounds into nuanced vibrations via handheld while the Hall Effect Joysticks and Triggers provide precise control, elevating your gaming experience with rich visual and tactile sensations.
With TECNO Pocket Go, users can enjoy a futuristic gaming experience, and seamlessly connecting to TECNO’s products in a new forms of AR experiences.
View original content:https://www.prnewswire.co.uk/news-releases/tecno-pocket-go-wins-global-product-technology-innovation-award-2024-at-ifa-2024-302241146.html
-
Artificial Intelligence6 days agoUNLEASHING INNOVATION: STARS OF SCIENCE SEASON 16 BEGINS SOON
-
Artificial Intelligence4 days agoAltair Names Collaboration Betters the World as Channel Partner for the EMEA Region
-
Artificial Intelligence7 days agoLG PRESENTS NEW APPLIANCE LINEUP WITH INDUSTRY-LEADING ENERGY EFFICIENCY AT IFA 2024
-
Artificial Intelligence5 days agoAutonomous Enterprise Market worth $114.0 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence6 days ago
Cloud Services Brokerage Market worth $26.2 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence6 days agoFlytxt Appoints Vickram Nagi as Senior Vice President and Head of Global Sales
-
Artificial Intelligence5 days agoAV-Comparatives Identifies Key Cybersecurity Threats for Summer 2024: Fakeshops, Phishing Attacks and Targeting Children
-
Uncategorized6 days agoNew US Consensus Report supports Nevisense
